Before Pfizer closed its takeover, Metsera reported weight loss of up to 14.1% in a phase 2b trial of the weekly regimen.

Beyond an oral version of its blockbuster weight loss drug Wegovy, which launched last month, Novo touted potential next-gen ...

In Phase II data released this week, people taking a monthly dose of PF’3944 continued to lose more weight than those on a ...

Pfizer acquired the candidate following a bidding war with obesity giant Novo Nordisk for Metsera.

Pfizer reported that its newly acquired weight loss drug showed promise as a monthly treatment, though the field is growing ...

Pfizer reported weight-loss results for a monthly GLP-1 obesity injection that it acquired as part of the $10 billion Metsera ...

Amgen is refusing U.S. regulators’ request to withdraw an inflammatory disease drug. Elsewhere, Pfizer battled skepticism on new obesity drug data, and Merck laid out its post-Keytruda future.

The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Pfizer and ...

Pfizer has spent billions of dollars on acquisitions in the past few decades. Its biggest deals include Warner-Lambert, ...